This study focuses on individuals with newly diagnosed advanced Ovarian Cancer that is HRD-negative, which means the cancer cells have a specific type of genetic profile related to how they repair their DNA. The purpose of this study is to compare a maintenance treatment using MK-2870, also known as sacituzumab tirumotecan, either alone or combined with bevacizumab, against the current standard medical care. Maintenance treatment refers to therapy given to keep the cancer from growing again after the initial main treatment has finished.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.